"Fc Fusion Molecules And Uses Thereof" in Patent Application Approval Process (USPTO 20240167011).
In: Gene Therapy Weekly, 2024-06-11, S. 3832-3832
serialPeriodical
Zugriff:
A patent application titled "Fc Fusion Molecules And Uses Thereof" has been made available online. The inventors describe a polypeptide called IdeS, which is an enzyme produced by the human pathogen S. pyogenes. IdeS has high substrate specificity for immunoglobulin G (IgG) and can cleave it into Fc and F(ab')2 fragments. The inventors propose variant Fc polypeptides and polypeptides with protease activity that can be used in various therapeutic applications, including treating diseases, improving gene therapy, and reducing pathogenic IgG antibodies. The patent application provides detailed claims and compositions related to these polypeptides. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Fc Fusion Molecules And Uses Thereof" in Patent Application Approval Process (USPTO 20240167011).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-06-11, S. 3832-3832 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|